On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1725-1731

  Bruland, O S ^a   Pihl, A ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Management; Osteosarcoma; Strategy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; LEXIDRONAM SAMARIUM SM 153; METHOTREXATE; MONOCLONAL ANTIBODY;

BONE CANCER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; HUMAN; LUNG METASTASIS; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0031406619     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00252-9     Document Type: Note

References (81)

1. Malawer MM, Unk MP, Donaldson SS. Sarcomas of bone. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia, JB Lippincott, 1989, 1418-1468.
2. Souhami R, Cannon SR. Osteosarcoma. In Peckham M, Pinedo HM, Veronesi U, eds. Oxford Textbook of Oncology. Oxford, Oxford University Press, 1995, 1969-1976.
3. Humphrey GB, Koops HS, Molenaar WM, Postma A. Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston, Kluwer Academic Publishers, 1993.
4. Novak J, McMaster JH. Frontiers of Osteosarcoma Research. Seattle, Hogrefe & Huber Publishers, 1993.
5. Dahlin DC. Bone Tumors: General Aspects and Data on 6, 221 Cases, 3rd edn. Springfield, Charles C Thomas, 1978.
6. Dahlin D, Unni K. Osteogenic sarcoma of bone and its important recognizable varieties. Am J Surg Pathol 1977, 1, 61-72.
7. Huvos AG. Osteogenic sarcoma. In Huvos AG, ed. Bone Tumors. Diagnosis, Treatment and Prognosis. Philadelphia, WB Saunders, 1991, 85-155.
8. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic Osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992, 10, 5-15.
9. Saeter G, Alvegârd TA, Elomaa I, Stenwig AE, Holmström T, Solheim ØP. Treatment of Osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group Study. J Clin Oncol 1991, 9, 1766-1775.
10. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic Osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993, 72, 3227-3238.
11. Winkler K, Bielack S, Delling G, et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologie tumor response in Osteosarcoma (study COSS-86). Cancer 1990, 66, 1703-1710.
12. Souhami RL, Chemotherapy for Osteosarcoma. Br J Cancer 1989, 59, 147-148.
13. Stiller CA. Population based survival rates for childhood cancer in Britain, 1980-91. BrMedJ 1994, 309, 1612-1616.
14. Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pédiatrie patients previously treated with intensive chemotherapy. J Clin Oncol 1994, 12, 2614-2620.
15. Saeter G, Høie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995, 75, 1084-1093.
16. Saner G, Bruland 0S, Follerâs G, Boysen M, Høie J. Extremity and non-extremity high-grade Osteosarcoma. The Norwegian Radium Hospitale experience during modern chemotherapy era. Acta Oncol 1996, 8, 129-134.
17. Meyers PA, Heller G, Healey JH, el al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993, 11, 449-153.
18. Bacci G, Briccoli A, Picci P, et al. Osteosarcoma of the extremities metastatic at presentation: results obtained with primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions. Cancer J, 1990, 3, 213-218.
19. Morgan E, Baum E, Bleyer WA, et al. Treatment of patients withmetastatic osteogenic sarcoma: a report from The Children's Cancer Study Group. Cancer Treat Rep 1984, 68, 661-664.
20. Dahlin DC, Coventry MB. Osteogenic sarcoma: a study of 600 cases. J Bone Joint Surg 1967, 49, 101-110.
21. Cade S. Osteogenic sarcoma: a study based on 133 patients. J R Coll Surg Edinb 1955, 1, 79-111.
22. Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 1972, 4, 482-510.
23. Harvei S, Solheim Ø. The prognosis in osteosarcoma: Norwegian National data. Cancer 1981, 48, 1719-1723.
24. Ruggieri P, De Cristofaro R, Picci P, et al. Complications and surgical indications in 144 cases of nonmetastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Clin Orthop 1993, 295, 226-238.
25. RougraffBT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg 1994, 76A, 649-656.
26. Gebhardt MC, Flugstad DI, Springfeld DS, Mankin HJ. The use of bone allografts for limb salvage in high grade extremity osteosarcoma. Clin Orthop 1991, 271, 181-196.
27. Sutow WW, Herson J, Ferez C. Survival after metastasis in osteosarcoma. Natl Cancer Inst Monogr 1981, 56, 227-231.
28. Beattie EJ, Harvey JC, Marcove R, Martini N. Results of multiple pulmonary resections for metastatic osteogenic sarcoma after two decades. J Surg Oncol 1991, 46, 154-155.
29. Roth JA, Putnam JBJ, Wesley MN, Rosenberg SA. Differing determinants of prognosis following resection of pulmonary métastases from osteogenic and soft tissue sarcoma patients. Cancer 1985, 55, 1361-1366.
30. van Rijk Zwikker GL, Nooy MA, Taminiau A, Kappetein AP, Huysmans HA. Pulmonary metastasectomy in patients with osteosarcoma. Eur J Cardiothorac Surg 1991, 5, 406-409.
31. Pastorino U, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. JClin Oncol 1991, 9, 1357-1362.
32. Cortes EP, Holland JF, Wang JJ, Sinks LF. Doxorubicin in disseminated osteosarcoma. JAMA 1972, 221, 1132-1138.
33. Jaffe N, Farber S, Traggis D. Favourable response of metastatic osteosarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 1973, 31, 1367-1373.
34. Ochs JJ' Cisdichlorodiamineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Symp 1978, 62, 239-245.
35. Rosen G. Phase II trial of cisplatinum in osteogenic sarcoma. ProcAm Soc Clin Oncol 1979, 20, 363-367.
36. Bowman LC. Activity of ifosfamide in metastatic and unresectable osteosarcoma. ProcAm Soc Clin Oncol 1979, 6, 214-217.
37. Goorin AM. Weekly high-dose methotrexate and doxorubicin for osteosarcoma: The Dana Farber Cancer Institute/The Children's Hospital Study III. J Clin Oncol 1987, 5, 1178-1184.
38. Bacci G, Gherlinzoni F, Picci P, et al. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol 1986, 22, 1337-1345.
39. Krailo M, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Children's Cancer Study Group. MedPed Oncol 1987, 15, 69-77.
40. Rosenberg SA, Chabner BA, Young RC, et al. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat Rep 1979, 63, 739-751.
41. Bramwell VHC, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992, 10, 1579-1591.
42. Rosen G, Caparros B, Huvos AG. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of primary tumor to preoperative chemotherapy. Cancer 1982, 49, 1221-1230.
43. Rosen G, Marcove RC, Caparros B, Nierenberg A, Koslof C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979, 43, 2163-2177.
44. Rosen G, Nirenberg A, Juergens H, Caparros B, Huvos AG. Response of primary osteogenic sarcoma to single-agent therapy with high-dose methotrexate with citrovorum factor rescue. Current Chemother Infect Dis 1980, 2, 1633-1635.
45. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 1985, 8, 659-664.
46. Eilber FR, Rosen G. Adjuvant chemotherapy for osteosarcoma. Semin Oncol 1989, 16, 312-323.
47. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol 1987, 4, 212-236.
48. Juergens H, Kosloff C, Nirenberg A, Mehta BM, Huvos AG, Rosen G. Prognostic factors in the response of primary osteogenic sarcoma to pre-operative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monogr 1981, 56, 221-226.
49. Bacci G, Picci P, Avella M, et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities. J Chemother 1992, 4, 189-195.
50. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994, 12, 423-431.
51. Guliano AE, Feig S, Eilber FR. Changing metastatic patterns of osteosarcoma. Cancer 1984, 54, 2160-2164.
52. Jaffe N, Smith E, Abelson HT, Frei III E. Osteogenic sarcoma: alterations in the pattern of pulmonary métastases with adjuvant chemotherapy. J Clin Oncol 1983, 1, 251-254.
53. Goorin AM, Shuster JJ, Baker A, et al. Changing pattern of pulmonary métastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol 1991, 9, 600-605.
54. Bacci G, Avella M, Picci P, et al. Metastatic patterns in osteosarcoma. Tumori 1988, 74, 421-427.
55. Tabone MD, Kalifa C, Rodary C. Osteosarcoma recurrences in pédiatrie patients previously treated with intensive chemotherapy. J Clin Oncol 1994, 12, 2614-2620.
56. Taylor WF, Irvins JC, Dahlin DC, Edmonson JH, Pritchard DJ. Trends and variability in survival from osteosarcoma. Mayo Clin Proc 1978, 53, 695-700.
57. Edmonson JH, Green SJ, Ivins 1C, et al. A controlled pilot study of high dose methotrexate as post-surgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 1984, 2, 152-156.
58. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986, 314, 1600-1606.
59. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987, 5, 21-26.
60. Taylor WF, Irvins JC, Pritchard DJ, Edmonson JH. Trends and variability in survival among patients with osteosarcoma. Mayo Clin Proc 1985, 60, 91-104.
61. Campanacci M, Bacci G, Bertoni F, et al. The treatment of osteosarcoma of the extremities: twenty years' experience at the Institute Ortopedico Rizzoli. Cancer 1981, 48, 1569-1581.
62. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985, 312, 1604-1608.
63. Bruland ØS, Saeter G, Pihl A. Dilemmas and challenges in the current management of osteosarcoma. A plea for more individualized treatment. Anticancer Res 1995, 15, 1798.
64. Blaney SM, Smith MA, Grem JL. Doxorubicin: role in the treatment of osteosarcoma. In Humphrey GB, Koops HS, Molenaar WM, Postma A, eds. Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston, Kluwer Academic Publishers, 1993, 55-73.
65. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991, 20, 1460-1470.
66. Bielack SS, Entmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 1996, 10, 1652-1660.
67. Ferrari S, Sassoli V, Orlandi M, et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993, 5, 135-141.
68. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994, 12, 1443-1451.
69. Delepine N, Delepine G, Gaetano B, et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic sarcoma: analysis of the literature. Cancer 1996, 78, 2127-2135.
70. Bieling P, Rehan N, Winkler P, et al. Tumor size as an important prognostic factor in osteosarcoma. J Clin Oncol 1996, 14, 848-859.
71. Bacci G, Picci P, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993, 71, 1224-1230.
72. Classer DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer 1992, 69, 698-708.
73. Bruland ØS, Høifødt H, Sæter G, Trônes GE, Fodstad Ø. Micrometastatic disease in patients with osteosarcoma. A pilot study using immunomagnetic detection of tumor cells in peripheral blood and bone marrow aspirates. Proc. 2nd Osteosarcoma Research Conference, Institute Ortopedico Rizzoli, Bologna Nov., 1996.
74. Bruland ØS, Aas M, Fodstad 0, et al. Immunoscintigraphy of bone sarcomas. Results in five patients. Eur J Cancer 1994, 30, 1484-1489.
75. Baldini N, Scotland! K, Barbanti-Brodano G, et al. Expression of p-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 1995, 21, 1380-1385.
76. Sonneveld P, Schoester M, deLeeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994, 12, 1584-1591.
77. Strander H, Bauer HCF, Brosjø O, et al. Adjuvant interferon treatment in human osteosarcoma. In Humphrey GB, Koops HS, Molenaar WM, Postma A, eds. Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston, Kluwer Academic Publishers, 1993, 29-32.
78. Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. In Humphrey GB, Koops HS, Molenaar WM, Postma A, eds. Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Boston, Kluwer Academic Publishers, 1993, 101-107.
79. 153Sm-EDTMP. A new promising approach. Acta Oncol 1996, 35, 381-384.
80. 153Sm-EDTMP in a recurrent canine osteosarcoma. J Small Animal Pract 1996, 37, 241-246.
81. 153SmEDTMP as primary treatment of high grade osteosarcoma of the spine. Acta Orthop Scand 1996, 67, 48.